215 related articles for article (PubMed ID: 33236399)
21. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
22. Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
Sutrave G; Blyth E; Gottlieb DJ
Cytotherapy; 2017 Nov; 19(11):1284-1301. PubMed ID: 28927824
[TBL] [Abstract][Full Text] [Related]
23. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
24. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.
Roex MCJ; van Balen P; Germeroth L; Hageman L; van Egmond E; Veld SAJ; Hoogstraten C; van Liempt E; Zwaginga JJ; de Wreede LC; Meij P; Vossen ACTM; Danhof S; Einsele H; Schaafsma MR; Veelken H; Halkes CJM; Jedema I; Falkenburg JHF
Leukemia; 2020 Mar; 34(3):831-844. PubMed ID: 31624377
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Van Besien K; Bachier-Rodriguez L; Satlin M; Brown MA; Gergis U; Guarneri D; Hsu J; Phillips AA; Mayer SA; Singh AD; Soave R; Rossi A; Small CB; Walsh TJ; Rennert H; Shore TB
Leuk Lymphoma; 2019 Jul; 60(7):1693-1696. PubMed ID: 30741059
[TBL] [Abstract][Full Text] [Related]
26. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
Laberko A; Bogoyavlenskaya A; Shelikhova L; Shekhovtsova Z; Balashov D; Voronin K; Kurnikova E; Boyakova E; Raykina E; Brilliantova V; Pirumova V; Novichkova G; Maschan A; Maschan M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
[TBL] [Abstract][Full Text] [Related]
28. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD; Lutzko C; Leemhuis T; Zhu X; Pham G; Ray L; Thomas S; Dourson C; Wilhelm J; Lane A; Cancelas JA; Lipps D; Ferrell J; Hanley PJ; Keller MD; Bollard CM; Wang YM; Davies SM; Nelson AS; Grimley MS
Blood Adv; 2022 May; 6(9):2897-2907. PubMed ID: 35108727
[TBL] [Abstract][Full Text] [Related]
29. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
30. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
[TBL] [Abstract][Full Text] [Related]
31. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
32. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
Front Immunol; 2020; 11():620891. PubMed ID: 33664733
[TBL] [Abstract][Full Text] [Related]
33. Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules.
D'Orsogna LJ; van den Heuvel H; van der Meer-Prins EM; Roelen DL; Doxiadis II; Claas FH
J Immunol; 2012 Nov; 189(10):4825-31. PubMed ID: 23077240
[TBL] [Abstract][Full Text] [Related]
34. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
[TBL] [Abstract][Full Text] [Related]
35. Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation.
Kállay K; Kassa C; Réti M; Karászi É; Sinkó J; Goda V; Stréhn A; Csordás K; Horváth O; Szederjesi A; Tasnády S; Hardi A; Kriván G
J Immunother; 2018 Apr; 41(3):158-163. PubMed ID: 29239916
[TBL] [Abstract][Full Text] [Related]
36. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
Freimüller C; Stemberger J; Artwohl M; Germeroth L; Witt V; Fischer G; Tischer S; Eiz-Vesper B; Knippertz I; Dörrie J; Schaft N; Lion T; Fritsch G; Geyeregger R
Cytotherapy; 2015 Jul; 17(7):989-1007. PubMed ID: 25866178
[TBL] [Abstract][Full Text] [Related]
37. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study.
Liu X; Wu M; Peng Y; Chen X; Sun J; Huang F; Fan Z; Zhou H; Wu X; Yu G; Zhang X; Li Y; Xiao Y; Song C; Xiang AP; Liu Q
Cell Transplant; 2014; 23(9):1087-98. PubMed ID: 23294601
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1).
Duncombe AS; Grundy JE; Oblakowski P; Prentice HG; Gottlieb DJ; Roy DM; Reittie JE; Bello-Fernandez C; Hoffbrand AV; Brenner MK
Blood; 1992 Jun; 79(11):3059-66. PubMed ID: 1316791
[TBL] [Abstract][Full Text] [Related]
39. Herpesvirus infections in hematopoietic stem cell transplant recipients seropositive for human cytomegalovirus before transplantation.
Fan J; Jing M; Yang M; Xu L; Liang H; Huang Y; Yang R; Gui G; Wang H; Gong S; Wang J; Zhang X; Zhao H; Gao H; Dong H; Ma W; Hu J
Int J Infect Dis; 2016 May; 46():89-93. PubMed ID: 27057748
[TBL] [Abstract][Full Text] [Related]
40. A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population.
Linn YC; Sundar Raj K; Teo B; Phang CY; Chittezhath M; Koh M
Cytotherapy; 2023 May; 25(5):510-520. PubMed ID: 36882347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
